Investigation of the therapeutic effect of vitamin D with selenium on antioxidant indices and hormonal changes and anti-thyroperoxidase antibody in patients with subclinical Hashimoto's thyroiditis and vitamin-D deficiency

Start Date21 Sep 2025

Sponsor / Collaborator

Isfahan University of Medical Sciences

100 Clinical Results associated with Selenium

100 Translational Medicine associated with Selenium

100 Patents (Medical) associated with Selenium

14,373

Literatures (Medical) associated with Selenium

01 Feb 2026·JOURNAL OF CRITICAL CARE

Antimicrobial-coated endotracheal tubes: A narrative review

Review

Author: Bebarta, Vikhyat S ; Richardson, Abigail K ; April, Michael D ; Rizzo, Julie A ; Smith, Matthew D ; Fuller, Robert G ; Douin, David J ; Schauer, Steven G ; Moran, Margaret M

INTRODUCTION:

Ventilator-associated pneumonia (VAP) is a significant source of morbidity and mortality. We sought to assess the current evidence on antimicrobial-coated endotracheal tubes (ETT) as one potential tool to break the cycle of colonization and infection among ICU patients.

METHODS:

We conducted a narrative review of available studies focused on the use of antimicrobial-coated ETTs to reduce VAP. The selection process adhered to PRISMA-ScR guidelines.

RESULTS:

A total of 58 studies met the inclusion criteria. Silver-based coatings were the most common, with 15 studies, including three randomized controlled trials and two systematic reviews. Of the 15 studies, 12 demonstrated a reduction in bacterial colonization. Two demonstrated delay of VAP onset and three demonstrated reduced VAP incidence. While one study determined there was a decreased mortality, three others determined no statistically significant difference could be proven in overall mortality, hospital stay. Additional research explored coatings composed of a noble metal alloy, zinc, selenium, antibiotics, biocides, and biomimetics. Novel surface modifications such as nano-roughening, micro-patterning, and photodynamic agents showed promise in preventing biofilm formation, though clinical validation remains limited.

CONCLUSIONS:

Many antimicrobial materials have undergone in vitro appraisal as potential ETT coatings to reduce VAP incidence, but only silver has been extensively tested in RCTs.

01 Jan 2026·BIOMATERIALS

In situ self-growth nano-selenium hydrogel coating alleviates surface thrombosis of blood-contacting devices by inactivating inflammatory cells

Article

Author: Hu, Yage ; Yang, Li ; Hu, Jinpeng ; Wang, Jiaqi ; Wang, Tong ; Zhang, Fanjun ; Wang, Yunbing ; Luo, Rifang ; He, Min ; Lai, Wei ; Wang, Lietao ; Xiong, Yao ; Zhang, Zhongwei

The formation of thrombi in blood-contacting devices is accompanied by a several risks that can be life-threatening. Specifically, the process of blood exposure immediately after implantation triggers an immune response aimed at removing foreign substances, which can lead to thrombosis, inflammation and device malfunction. To confer anticoagulant properties to the implanted devices, a nano-selenium hydrogel coating which was in-situ self-growing on implant devices had been developed that inhibited thrombosis by intervening in the inflammatory cell activation pathway, possibly by decreasing tissue factor activity and thrombin production expressed by inflammatory cells. Compared with the selenium-free coating, the nano-selenium hydrogel coating significantly inhibited macrophage activation, as demonstrated by reduced M1 phenotype and increased M2 phenotype polarization, resulting in a 146 % increase in the M2/M1 ratio, together with the reduction of secretion of pro-inflammatory cytokines. More importantly, the selenium coating reduced macrophage procoagulant activity through macrophage inactivation, resulting in decreased tissue factor (TF) release and thrombin production. Remarkably, the coating suppressed the coagulation response in a rabbit model of LPS-induced inflammation and in patients with clinical sepsis, thereby reducing thrombus formation manifested by decreased fibrin deposition and reduced monocyte markers. Further studies demonstrated that coated central venous catheters (CVCs) in rabbit and pig vascular models diminished thrombosis and vascular inflammatory activation. Overall, this active anti-inflammatory hydrogel coating strategy is effective in inhibiting thrombus formation on blood-contacting device surfaces, especially in more challenging bloodstream environments.

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Does dietary selenium protect against suicidal ideation? Findings from a U.S. population study

Article

Author: Liu, Haobiao ; Chen, Zhuohang

BACKGROUND:

Suicidal ideation represents a significant public health challenge globally. Emerging evidence indicates that nutritional factors may offer protective effects on mental health. However, the association between dietary selenium intake and suicidal ideation remains inadequately explored.

METHODS:

Using data from the National Health and Nutrition Examination Survey, we employed logistic regression models to evaluate this association, with results reported as odds ratios (ORs) and 95 % confidence intervals (CIs), adjusting for demographic, lifestyle, and health-related variables. Restricted cubic splines (RCS) were applied to investigate potential non-linear relationships.

RESULTS:

A total of 23,942 participants were included in the final analysis. After adjusting for relevant covariates, higher dietary selenium intake was significantly associated with a reduced suicidal ideation risk. In the fully adjusted model, each unit increase in selenium intake corresponded to a 41 % decrease in the odds of suicidal ideation (OR = 0.59, 95 % CI: 0.41-0.85, P = 0.005). Participants in higher quartiles of selenium intake exhibited a notably lower risk of suicidal ideation compared to those in the lowest quartile. Specifically, the ORs for the higher quartiles were 0.67 (95 % CI: 0.50-0.88, P = 0.005), 0.63 (95 % CI: 0.44-0.91, P = 0.015), and 0.59 (95 % CI, 0.39-0.89, P = 0.014), respectively. RCS analysis further revealed a linear negative association (P for nonlinearity = 0.942), suggesting a protective effect linked to increased selenium consumption.

CONCLUSIONS:

These findings underscore the potential role of dietary selenium in supporting mental health and suicide prevention. Further prospective studies and investigations into the underlying biological mechanisms are essential to validate these results and elucidate the pathways involved.

News (Medical) associated with Selenium

27 Oct 2025

·www.einpresswire.com

64K Cellssense Featured in Frontiers in Aging for Pioneering Review on Nanoengineered Mitochondria

Company outlines how nanoengineering approaches may advance studies of mitochondrial function and cellular health. This publication in Frontiers in Aging represents a synthesis of emerging data on mitochondrial nanoengineering, reflecting our commitment to peer-reviewed science and measurable longevity research.” — Thomas Miller, Head of the 64K Cellssense International Research Center LAUSANNE, SWITZERLAND, October 27, 2025 / EINPresswire.com / -- 64K Cellssense announced its Research and Innovation Center published a review article in Frontiers in Aging , a leading Swiss academic journal. The article, titled “Nanoengineered Mitochondria for Mitochondrial Dysfunction and Anti-Aging Interventions,” explores the emerging field of mitochondrial nanoengineering and its implications for maintaining cellular function and energy balance. The review provides a comprehensive overview of recent advances in nanoengineered mitochondria — a rapidly growing focus in life sciences. It details how nanoscale design can support mitochondrial integrity, optimize metabolic efficiency, and enhance resilience under cellular stress. The review offers an international perspective on how nanotechnology is shaping next-generation mitochondrial research, reflecting 64K Cellssense’s contribution to the global dialogue on healthy cellular aging. Within 64K Cellssense’s 12-Dimensional Longevity Framework, mitochondrial performance is studied as a core determinant of cellular function. The review proposes a research framework that integrates nanoengineering strategies to optimize mitochondrial energy systems and mitigate oxidative imbalance at the cellular level. The article also summarizes key natural mitochondrial regulators — including α-ketoglutarate (AKG), ergothioneine (EGT), resveratrol, CoQ10, and selenium — and highlights how nano-delivery approaches may improve their stability and targeted bioavailability in experimental models. Building on these foundational insights, 64K Cellssense continues to develop its proprietary MPNutria ® Nano-Nutrition Delivery Technology, based on metal–phenolic network (MPN) nanostructures — a technology lineage related to the 2025 Nobel Prize -winning research on metal-organic frameworks (MOFs). This technology exemplifies how the brand translates cutting-edge scientific concepts into scalable, experimentally validated applications. While mitochondrial nanoengineering shows considerable potential, the review notes that further research is required to address challenges related to delivery consistency, biological compatibility, and scalable production. The Research and Innovation Center of 64K Cellssense has collaborated on projects with academic and clinical partners in Switzerland, the United States, Australia and China, including, among others, ETH Zurich, Harvard University and Clinique Eden Suisse. Collectively, these efforts reinforce 64K Cellssense’s long-term mission to drive data-driven innovation in cellular health, bridging academic research and practical, scalable applications in life sciences. Anastasia Y. Vitagenix Technology Limited email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

14 Mar 2025

·www.drugs.com

Metal Mixtures During Pregnancy May Lower Midlife Hypertension Risk

FRIDAY, March 14, 2025 -- Optimizing copper, manganese, and vitamin B12 during pregnancy can help lower the risk for high blood pressure and hypertension in midlife, according to a study published online March 6 in Hypertension to coincide with the American Heart Association Epidemiology and Prevention/Lifestyle and Cardiometabolic Health 2025 Scientific Sessions, held from March 6 to 9 in New Orleans. Mingyu Zhang, Ph.D., from Harvard Medical School in Boston, and colleagues measured nonessential and essential metals in red blood cells along with folate and vitamin B12 in plasma during pregnancy (participants enrolled 1999 to 2002) to examine long-term associations with midlife blood pressure and hypertension. Midlife blood pressure was measured from 2017 to 2021. A total of 493 women were followed for a median of 18.1 years. The researchers found that a doubling of copper and manganese was associated with 0.75 and 0.80 times the risk for hypertension, respectively, after adjustment. A slightly increased risk for hypertension was seen in association with higher cesium and selenium, but the 95 percent confidence intervals were wide and crossed the null. A doubling of vitamin B12 was associated with 3.64- and 2.52-mm Hg lower systolic and diastolic blood pressure, respectively. There was a monotonic association for the essential metal mixture with lower blood pressure, while threshold effects were seen for its association with hypertension. "These findings suggest that optimizing essential metal levels during pregnancy, particularly, copper and manganese, along with vitamin B12, may offer protective benefits against high blood pressure and hypertension in midlife," the authors write.

AHAClinical Study

07 Mar 2025

·www.drugs.com

Select Vitamins, Minerals During Pregnancy Protect Heart Health Later

FRIDAY, March 7, 2025 -- Getting essential vitamins and minerals during pregnancy can help a woman maintain healthy blood pressure into middle age, new research suggests. High levels of the minerals copper and manganese in pregnant women were associated with lower blood pressure decades later, as well as a reduced risk of high blood pressure , researchers reported. Higher levels of vitamin B12 also were associated with lower blood pressure in later life, according to findings published March 6 in the journal Hypertension . “Optimizing these essential metals, minerals and vitamins -- particularly copper, manganese and vitamin B12 -- during pregnancy may offer protective benefits against hypertension in midlife, an especially critical time period for women’s future cardiovascular risk in later life,” lead researcher Mingyu Zhang , an epidemiologist at Beth Israel Deaconess Medical Center in Boston, said in a news release. For the study, his team analyzed data from an ongoing long-term study of nearly 500 pregnant women recruited between 1999 and 2002. The women underwent blood testing during their pregnancy for their levels of healthy essential minerals, such as copper, magnesium, manganese, selenium and zinc, researchers said. They also were tested for levels of folate and vitamin B12. After nearly 20 years of follow up, researchers checked in again with the women, who’d now reached an average age of 51. The women’s blood pressure was tested during this check in, and was considered high if greater than 130/80 or if they’d been prescribed high blood pressure meds. Results showed that if women had doubled levels of copper and manganese in their blood during pregnancy, their risk of midlife high blood pressure was 25% and 20% lower, respectively. Doubled levels of vitamin B12 also contributed to lower blood pressure, but researchers noted that about 95% of participants had B12 levels within the normal range. Copper, manganese, selenium and zinc all lowered blood pressure, and the higher the levels, the more blood pressure benefitted later in life, researchers found. However, the findings should not be interpreted as recommendations, since researchers were unable to tell whether women got these vitamins and minerals from food, dietary supplements or other sources, Zhang said. “More research including clinical trials is needed to determine the optimal dietary intake of these minerals and micronutrients,” Zhang said. Researchers hope to ultimately identify women at high risk for developing high blood pressure later in life and intervene during pregnancy, either with enhanced nutrition or supplements. These results were scheduled for presentation Saturday at an American Heart Association meeting in New Orleans. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical Study

100 Deals associated with Selenium

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Cardiotoxicity	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Chagas Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Chronic Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
end organ damage	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Functional disorder	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Huntington Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Infarction	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Keshan Disease	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008
Myocardial Infarction	Phase 3	Brazil	Fundação Oswaldo Cruz	31 Oct 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2018	Phase 1	Female Genital Neoplasms	-	Selenious acid/carboplatin/paclitaxel	ryotagrixt(ziycgfowwx) = gzgneqmgvx pzjjvecllg (tknvqsozet ) View more	-	01 Jul 2018
ASCO2014	Not Applicable	Second Primary Neoplasms	-	Selenium	njerqezlle(fxfolhdacm) = hyarvxkptk ruzclylcfz (vetghmkgjx, 0.77 - 2.38)	-	20 May 2014
				Placebo	njerqezlle(fxfolhdacm) = cbwdqsxlvi ruzclylcfz (vetghmkgjx )
Pubmed \| Cochrane Database Syst Rev	Not Applicable	Hashimoto Disease	463	Selenium supplementation	amhmkmrjct(dyrzrmjpae): RR = 4.67 (95% CI, 1.61 - 13.5), P-Value = 0.004	-	06 Jun 2013
				Selenium
ASCO 12010 \| ASCO 22010	Phase 3	Non-small cell lung cancer stage I	-	selenium (Se) supplementation (Selenized yeast 200 micrograms)	kkxwaohveb(glajpkllzi) = czxrubsngq eeadumntlb (qkatretwxf ) View more	Negative	20 Jun 2010
				Placebo	kkxwaohveb(glajpkllzi) = purijkymvu eeadumntlb (qkatretwxf ) View more
German Working Group on Trace Elements and Electrolytes (ASTRO2009)	Phase 2	Head and Neck Neoplasms selenium deficiency	40	Selenium supplementation	acrfvhfmoq(qbnlgfaqse) = lpmcttmxwg oyjvwjwgzn (xejkclzsat ) View more	Negative	01 Nov 2009
				Control group (no selenium supplementation)	acrfvhfmoq(qbnlgfaqse) = bxtailwfym oyjvwjwgzn (xejkclzsat ) View more
ASCO2009	Phase 2	Head and Neck Neoplasms	39	selenium (Group A)	xebvkacuhg(uttjzjenyg) = keepevgubd jsxjughias (zbyfyzgwas ) View more	Negative	20 May 2009
				selenium (Group B)	xebvkacuhg(uttjzjenyg) = yemometosy jsxjughias (zbyfyzgwas ) View more
ASCO2008	Phase 2	Prostatic Cancer	140	Placebo	okmsyrujrl(upayfttnxj) = bhrsjwrqxb ktygibflbw (hylmucijve )	Negative	20 May 2008
				200µg/day Selenium	okmsyrujrl(upayfttnxj) = ztahzhezhd ktygibflbw (hylmucijve )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Selenium

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation